Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
PGNX > SEC Filings for PGNX > Form 8-K on 22-Oct-2013All Recent SEC Filings

Show all filings for PROGENICS PHARMACEUTICALS INC

Form 8-K for PROGENICS PHARMACEUTICALS INC


22-Oct-2013

Other Events


Item 8.01. Other Events.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) recently presented data on two of its PSMA-focused technologies, at the European Association of Nuclear Medicine (EANM) Annual Congress in Lyon, France (October 21), and the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston (October 19 - 23).

At EANM's Annual Congress, Dr. Shankar Vallabhajosula, Professor of Radiochemistry at Cornell Medical College, presented data from a phase 1 clinical study of eight patients undergoing radical prostatectomy. In these patients, 99mTc-MIP 1404, a radiopharmaceutical imaging agent candidate currently in a phase 2 international multicenter study by Progenics' Molecular Insight subsidiary, detected primary metastatic prostate cancer and metastatic lesions in both soft tissue and bone with high specificity. 99mTc uptake in lesions correlated well with both Gleason Scores and PSMA expression in the phase 1 study.

At the AACR Conference, Progenics scientists Jose Murga and Yakov Rotshteyn presented findings from studies of PSMA ADC, the company's antibody-drug conjugate candidate in a phase 2 study for the treatment of metastatic castration-resistant prostate cancer.

Additional data and information are included in the presentations which are available for the next 30 days in the Media Center of the company's website, www.progenics.com.


  Add PGNX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for PGNX - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.